PURPOSE: The goal of three-dimensional (3-D) conformal radiation is to increase the dose delivered to tumor while minimizing dose to surrounding normal brain. Previously it has been shown that even escalated doses of 70 to 80 Gy have failure patterns that are predominantly local. This article describes the failure patterns and survival seen with high-grade gliomas given 90 Gy using a 3-D conformal intensity-modulated radiation technique. PATIENTS AND METHODS: From April 1996 to April 1999, 34 patients with supratentorial high-grade gliomas were treated to 90 Gy. For those that recurred, failure patterns were defined in terms of percentage of recurrent tumor located within the high-dose region. Recurrences with more than 95% of their volume within the high-dose region were considered central; those with 80% to 95%, 20% to 80%, and less than 20% were considered in-field, marginal, and distant, respectively. RESULTS: The median age was 55 years, and median follow-up was 11.7 months. At time of analysis, 23 (67.6%) of 34 patients had developed radiographic evidence of recurrence. The patterns of failure were 18 (78%) of 23 central, three (13%) of 23 in-field, two (9%) of 23 marginal, and zero (0%) of 23 distant. The median survival was 11.7 months, with 1-year survival of 47.1% and 2-year survival of 12.9%. No significant treatment toxicities were observed. CONCLUSION: Despite dose escalation to 90 Gy, the predominant failure pattern in high-grade gliomas remains local. This suggests that close margins used in highly conformal treatments do not increase the risk of marginal or distant recurrences. Our results indicate that intensification of local radiotherapy with dose escalation is feasible and deserves further evaluation for high-grade gliomas.
PURPOSE: The goal of three-dimensional (3-D) conformal radiation is to increase the dose delivered to tumor while minimizing dose to surrounding normal brain. Previously it has been shown that even escalated doses of 70 to 80 Gy have failure patterns that are predominantly local. This article describes the failure patterns and survival seen with high-grade gliomas given 90 Gy using a 3-D conformal intensity-modulated radiation technique. PATIENTS AND METHODS: From April 1996 to April 1999, 34 patients with supratentorial high-grade gliomas were treated to 90 Gy. For those that recurred, failure patterns were defined in terms of percentage of recurrent tumor located within the high-dose region. Recurrences with more than 95% of their volume within the high-dose region were considered central; those with 80% to 95%, 20% to 80%, and less than 20% were considered in-field, marginal, and distant, respectively. RESULTS: The median age was 55 years, and median follow-up was 11.7 months. At time of analysis, 23 (67.6%) of 34 patients had developed radiographic evidence of recurrence. The patterns of failure were 18 (78%) of 23 central, three (13%) of 23 in-field, two (9%) of 23 marginal, and zero (0%) of 23 distant. The median survival was 11.7 months, with 1-year survival of 47.1% and 2-year survival of 12.9%. No significant treatment toxicities were observed. CONCLUSION: Despite dose escalation to 90 Gy, the predominant failure pattern in high-grade gliomas remains local. This suggests that close margins used in highly conformal treatments do not increase the risk of marginal or distant recurrences. Our results indicate that intensification of local radiotherapy with dose escalation is feasible and deserves further evaluation for high-grade gliomas.
Authors: Robert B Den; Mitchell Kamrava; Zhi Sheng; Maria Werner-Wasik; Erin Dougherty; Michelle Marinucchi; Yaacov R Lawrence; Sarah Hegarty; Terry Hyslop; David W Andrews; Jon Glass; David P Friedman; Michael R Green; Kevin Camphausen; Adam P Dicker Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-09 Impact factor: 7.038
Authors: P Farace; M G Giri; G Meliadò; D Amelio; L Widesott; G K Ricciardi; S Dall'Oglio; A Rizzotti; A Sbarbati; A Beltramello; S Maluta; M Amichetti Journal: Br J Radiol Date: 2010-11-02 Impact factor: 3.039
Authors: Christina I Tsien; Doris Brown; Daniel Normolle; Matthew Schipper; Morand Piert; Larry Junck; Jason Heth; Diana Gomez-Hassan; Randall K Ten Haken; Thomas Chenevert; Yue Cao; Theodore Lawrence Journal: Clin Cancer Res Date: 2011-11-07 Impact factor: 12.531
Authors: Kruttika Bhat; Mohammad Saki; Erina Vlashi; Fei Cheng; Sara Duhachek-Muggy; Claudia Alli; Garrett Yu; Paul Medina; Ling He; Robert Damoiseaux; Matteo Pellegrini; Nathan R Zemke; Phioanh Leia Nghiemphu; Timothy F Cloughesy; Linda M Liau; Harley I Kornblum; Frank Pajonk Journal: Proc Natl Acad Sci U S A Date: 2020-05-01 Impact factor: 11.205
Authors: Brian E Lally; Geoffrey A Geiger; Steven Kridel; Alice E Arcury-Quandt; Michael E Robbins; Nancy D Kock; Kenneth Wheeler; Prakash Peddi; Alexandros Georgakilas; Gary D Kao; Constantinos Koumenis Journal: Cancer Res Date: 2007-09-15 Impact factor: 12.701
Authors: L R Kleinberg; V Stieber; T Mikkelsen; K Judy; J Weingart; G Barnett; J Olson; S Desideri; X Ye; S Grossman Journal: J Radiat Oncol Date: 2015-08-05
Authors: John M Watkins; David T Marshall; Sunil Patel; Pierre Giglio; Amy E Herrin; Elizabeth Garrett-Mayer; Joseph M Jenrette Journal: J Neurooncol Date: 2009-01-14 Impact factor: 4.130